Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.15%), COSCO Shipping Energy (70.05%), and GCL-Poly Energy (69.20%) [1] - The largest increases in holding amounts over the last five trading days were seen in the Tracker Fund of Hong Kong (+39.80 billion), China National Offshore Oil Corporation (+17.62 billion), and Hua Hong Semiconductor (+16.45 billion) [1] - The largest decreases in holding amounts were recorded for Alibaba-W (-15.35 billion), Li Auto-W (-12.16 billion), and Innovent Biologics (-7.70 billion) [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding ratio of 71.15% with 9.874 billion shares [1] - COSCO Shipping Energy (01138) has a holding ratio of 70.05% with 908 million shares [1] - GCL-Poly Energy (01330) has a holding ratio of 69.20% with 280 million shares [1] Group 2: Recent Increases in Holdings - Tracker Fund of Hong Kong (02800) saw an increase of +39.80 billion in holding amount, with a change of +15.154 million shares [1] - China National Offshore Oil Corporation (00883) increased by +17.62 billion, with +8.613 million shares added [1] - Hua Hong Semiconductor (01347) increased by +16.45 billion, with +2.138 million shares added [1] Group 3: Recent Decreases in Holdings - Alibaba-W (09988) experienced a decrease of -15.35 billion, with a reduction of -0.94078 million shares [2] - Li Auto-W (02015) saw a decrease of -12.16 billion, with -1.50328 million shares reduced [2] - Innovent Biologics (01801) had a decrease of -7.70 billion, with -0.85364 million shares reduced [2]

Group 1 - The core viewpoint of the articles highlights the strong performance of public funds in the third quarter, with 55 funds achieving a net value growth rate exceeding 100% year-to-date, indicating a positive investment experience for holders [1][2] - A significant portion of these high-performing funds, including those focused on innovative pharmaceuticals and advanced manufacturing, have substantial management scales exceeding 10 billion yuan, demonstrating a commitment to long-term investment strategies [1][2] - The innovative pharmaceutical fund has consistently held top positions in quality pharmaceutical companies, with over 70% of its total market value concentrated in its top ten holdings, reflecting a strong belief in the potential of the pharmaceutical sector [1] Group 2 - The advanced manufacturing fund, with a management scale over 10 billion yuan, has also shown a focus on key industrial stocks, with over 40% of its total assets in its top ten holdings, indicating a strategic approach to investment [2] - Analysts note that China's innovation-driven policies have accelerated the development of core technology sectors such as artificial intelligence and semiconductors, creating favorable conditions for funds focused on high-growth areas [2] - The successful performance of many funds in the first three quarters of the year is attributed to three core characteristics: industry focus, low turnover rates, and consistent strategies, which align with the principles of long-term investment [2][3]

Core Insights - On November 3, 2025, Alibaba-W (09988), SMIC (00981), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.151 billion, 2.865 billion, and 2.054 billion respectively [1] Group 1: Southbound Trading Activity - Alibaba-W (09988) had a trading amount of 3.151 billion with a net buy of -96.034 million [2] - SMIC (00981) recorded a trading amount of 2.865 billion with a net buy of -1.149 billion [2] - Xiaomi Group-W (01810) achieved a trading amount of 2.054 billion with a net buy of +293 million [2] - Tencent Holdings (00700) had a trading amount of 1.324 billion with a net buy of +401 million [2] - China National Offshore Oil Corporation (00883) also had a trading amount of 1.324 billion with a net buy of +465 million [2] - Hua Hong Semiconductor (01347) reported a trading amount of 1.125 billion with a net buy of -568 million [2] - Pop Mart International (09992) had a trading amount of 750 million with a net buy of +130 million [2] - Sanofi (01530) recorded a trading amount of 718 million with a net buy of +324 million [2] - Innovent Biologics (01801) had a trading amount of 708 million with a net buy of +281 million [2] - CanSino Biologics (09926) achieved a trading amount of 673 million with a net buy of +373 million [2]

Core Insights - The article highlights that Innovent Biologics has achieved a significant milestone with its GCG/GLP-1 dual receptor agonist, Ma Shidu Peptide, demonstrating superior efficacy in blood glucose control and weight management compared to Semaglutide in the DREAMS-3 Phase III clinical trial [1][3][4] Group 1: Clinical Trial Results - The DREAMS-3 trial is the first head-to-head Phase III clinical study comparing a GCG/GLP-1 dual receptor agonist with Semaglutide in diabetes treatment, marking a breakthrough for domestic innovative drugs [1][3] - After 32 weeks of treatment, 48% of Ma Shidu Peptide patients achieved both blood glucose targets (HbA1c < 7.0%) and weight loss of ≥10%, significantly higher than the 21% in the Semaglutide group [3][4] - Ma Shidu Peptide showed an average blood glucose reduction of 2.03% compared to 1.84% for Semaglutide, and an average weight loss of 10.29% versus 6.00% [3][4] Group 2: Safety and Tolerability - The overall tolerability of Ma Shidu Peptide is good, with a low discontinuation rate due to adverse events and no new safety signals reported [4] - Common adverse events were mild to moderate gastrointestinal reactions, with a low incidence of hypoglycemia comparable to Semaglutide, and no reports of severe hypoglycemia [4] Group 3: Market Potential and Innovation - The GLP-1 drug market is projected to exceed $100 billion by 2030, driven by strong demand for effective and safe treatments for obesity and metabolic disorders [6] - Ma Shidu Peptide is the first and only GCG/GLP-1 dual receptor agonist approved for both weight management and type 2 diabetes treatment, positioning it as a competitive player in the market [6][8] - The innovative design of the injection pen, featuring a hidden needle and single-use format, enhances patient convenience and compliance, which is crucial for long-term treatment adherence [6][8]

Group 1 - Xiaomi Group has seen a net buy of HKD 1.029 billion, with a total of HKD 19.1269 billion net bought over four consecutive days [1] - CNOOC reported a net buy of HKD 0.993 billion, totaling HKD 16.0304 billion net bought over three consecutive days [1] - Tencent Holdings experienced a net sell of HKD 1.51 billion, with a total of HKD 19.9056 billion net sold over four consecutive days [1] Group 2 - Xiaomi's automotive division announced that it will deliver over 40,000 vehicles by October 2025, with a significant reduction in delivery times due to increased production capacity [3] - CNOOC's Q3 revenue reached CNY 104.895 billion, a year-on-year increase of 5.7%, while net profit decreased by 12.2% [3] - China Mobile, along with China Unicom and China Telecom, has received approval to conduct commercial trials for eSIM mobile services, which are expected to enhance user communication needs and provide opportunities for domestic software and systems [4]

Core Insights - The Hong Kong stock market saw a net inflow of 54.72 billion HKD from northbound trading on November 3, with 13.04 billion HKD from the Shanghai Stock Connect and 41.68 billion HKD from the Shenzhen Stock Connect [1] Group 1: Stock Performance - The most net bought stocks included Xiaomi Group-W (01810), CNOOC (00883), and China Mobile (00941) [1] - The most net sold stocks were SMIC (00981), Alibaba-W (09988), and Hua Hong Semiconductor (01347) [1] Group 2: Individual Stock Analysis - Xiaomi Group-W (01810) received a net inflow of 10.29 billion HKD, with Citigroup estimating that its electric vehicle deliveries exceeded 40,000 units in October, bringing the year-to-date total to over 308,000 units, achieving 88% of its 2025 target of 350,000 units [5] - CNOOC (00883) saw a net inflow of 9.93 billion HKD, with OPEC+ announcing a production increase of 137,000 barrels per day in December, while also planning to pause production increases from January to March next year [5] - Kangfang Biopharma (09926) had a net inflow of 3.72 billion HKD, as its dual-specific antibody drug was included in the breakthrough therapy designation list, accelerating its clinical development [6] - Three-Sixty Biopharma (01530) received a net inflow of 3.25 billion HKD, with Pfizer starting two global Phase III clinical trials for its dual-specific antibody [6] - Innovent Biologics (01801) had a net inflow of 2.96 billion HKD, reporting a 40% year-on-year increase in total product revenue for Q3 2025 and forming a global strategic partnership with Takeda Pharmaceutical [7] Group 3: Market Trends - There is a continued reduction in holdings of semiconductor stocks, with SMIC (00981) and Hua Hong Semiconductor (01347) experiencing net outflows of 1.38 billion HKD and 628 million HKD, respectively [7] - China Mobile (00941) and Pop Mart (09922) received net inflows of 461 million HKD and 52.96 million HKD, respectively, while Tencent (00700) and Alibaba-W (09988) faced net outflows of 151 million HKD and 955 million HKD [7]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The rhythm of innovative drug licensing-out transactions has recovered, with a total of 103 transactions and a total amount of $92.03 billion in the first three quarters of 2025, representing a 77% increase compared to the total amount for 2024 [2] - The research and CXO sectors continue to lead the recovery in the pharmaceutical industry, with significant profit growth in these areas [4] - The medical device bidding market has shown a steady recovery, with a year-on-year growth of 29.8% in the third quarter of 2025 [5] - The self-immune field has seen breakthroughs in overseas licensing, indicating a growing alignment with global R&D trends [6] - The weight loss market is experiencing competitive mergers and acquisitions, highlighting its attractiveness and potential impact on Chinese companies [7] - Trends in respiratory infectious diseases are expected to influence the demand for detection and treatment medications [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.74 percentage points in the last week, ranking 9th among 31 primary industry indices [21] - In the last month, the pharmaceutical industry underperformed the CSI 300 index by 1.83 percentage points, ranking 24th [25] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 38.80, above the five-year historical average of 31.26 [42] 3. Recent Research Achievements - The report highlights various recent research outputs, including weekly industry reports and insights on innovative drug licensing trends [48] 4. Recent Industry Policies and News - The National Healthcare Security Administration has initiated reforms for immediate settlement of medical insurance funds, aiming for 80% coverage by the end of 2025 [50] - Recent news includes significant breakthroughs in GLP-1 therapies and the approval of new drugs for chronic hepatitis B [51][52] 5. Recommended Companies and Profit Forecasts - The report provides a list of recommended companies with their respective EPS and PE ratios, indicating a positive outlook for several firms in the pharmaceutical sector [10]

Core Viewpoint - The innovative drug sector has rebounded strongly since September, driven by the upcoming 2025 National Negotiation, with significant trading activity observed in the Hang Seng Innovative Drug ETF (520500) on the first trading day of November [1]. Group 1: Market Activity - The Hang Seng Innovative Drug ETF (520500) recorded a half-day trading volume of 1.105 billion yuan on November 1, 2025, indicating active market participation [1]. - The ETF's trading volume has increased significantly, with total trading amounts of 604 million yuan and 1.654 billion yuan on October 30 and 31, respectively, compared to an average daily trading volume of 584 million yuan since October [1]. Group 2: Policy Developments - The 2025 National Medical Insurance Directory negotiations commenced on October 30, 2025, introducing a commercial health insurance innovative drug directory, marking a shift from a "basic insurance only" model to a "medical insurance + commercial insurance" collaborative payment approach [1]. - A total of 535 drug generic names were approved for the basic drug directory, while 121 were approved for the commercial insurance innovative drug directory, with 79 names submitted for both directories [1]. Group 3: Industry Outlook - The establishment of the commercial insurance innovative drug directory is expected to diversify payment methods, particularly benefiting high-value innovative drugs and multinational pharmaceutical products, potentially opening up new growth opportunities for the industry [1]. - The Hang Seng Innovative Drug ETF (520500) is designed to track companies involved in innovative drug research, development, and production, focusing on firms with strong R&D capabilities [1]. - As of October 31, 2025, the top five constituents of the index include BeiGene, China Biologic Products, Innovent Biologics, Kelun-Biotech, and CanSino Biologics, reflecting the index's focus on high-potential companies in the innovative drug sector [1].

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown significant market activity, with a recent increase of 3.38% and a trading volume of 170 million yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) reached a new high in both scale and shares since its inception as of October 31 [1] - The ETF has experienced net inflows for 4 out of the last 5 trading days, totaling 18.9 million yuan [1] - The index it tracks, the National Certificate Hong Kong Stock Connect Innovative Drug Index, rose by 3.67%, with notable increases in component stocks such as Senhwa Biosciences (up 10.11%) and Kanglongda (up 8.80%) [1] Group 2: Policy and Industry Insights - The ongoing negotiations for the National Medical Insurance drug list are complemented by a new commercial health insurance innovative drug directory, aimed at providing new payment channels for high-value innovative drugs [1] - The CAR-T cell drug, Rukiyou Lunsai injection from WuXi AppTec, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, with a listed price of 1.29 million yuan per injection [1] - Open Source Securities notes that the current innovative drugs included in both medical insurance and commercial insurance are in the early stages of volume growth, with potential for rapid revenue increases as policies continue to support innovative drugs [2] Group 3: Institutional Investment Trends - According to Guotou Securities, the proportion of all funds heavily invested in Biotech innovative drug companies has increased to 27.53%, reflecting a 2.61 percentage point rise, indicating growing institutional interest in the innovative drug sector [2] - The increasing allocation of funds to the innovative drug sector suggests a strong market recognition of its long-term development potential [2]

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced a significant rebound on November 3, with the innovative drug ETF (520880) showing a volatility of over 4.4% and a trading volume exceeding 500 million yuan, indicating strong bullish sentiment [1] - Key stocks such as Kangfang Biotech, Xiansheng Pharmaceutical, and Kangnuo Ya-B saw increases of nearly 6%, while other companies like Yuanda Pharmaceutical and Rongchang Biotech also experienced substantial gains [1] - The National Medical Insurance negotiation, which began on October 30, is expected to conclude with results announced in early December, introducing a new "commercial insurance innovative drug catalog" mechanism for the first time [1] Group 2 - Fund manager Feng Chen indicated that the innovative drug market could see a resurgence, suggesting that now may be a high-probability period for medium to long-term investments in innovative drugs [2] - The recent meeting between US and Chinese leaders has alleviated previous risks that suppressed the sector's performance, potentially allowing previously withdrawn funds to re-enter the market [2] - The current earnings season has shown strong performance from companies like Innovent Biologics and Hengrui Medicine, boosting confidence in the sector [2] Group 3 - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses entirely on innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [3] - As of the end of September, the index has seen a year-to-date increase of 108.14%, outperforming other innovative drug indices [3] - The ETF has a fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF tracking this index [3]